AJ1-11095
Myelofibrosis (Primary, Post-Polycythemia Vera, Post-Essential Thrombocythemia)
Phase 1Active
Key Facts
Indication
Myelofibrosis (Primary, Post-Polycythemia Vera, Post-Essential Thrombocythemia)
Phase
Phase 1
Status
Active
Company
About Ajax Therapeutics
Ajax Therapeutics is a private, pre-revenue biotech advancing a novel Type II JAK2 inhibitor, AJ1-11095, currently in Phase 1 for myelofibrosis. The company's platform leverages state-of-the-art computational methods to design highly selective kinase inhibitors aimed at addressing disease persistence and reducing mutant allele burden, unmet needs with current standard-of-care. Led by a seasoned management team with deep experience in hematology and venture capital, Ajax is targeting a significant opportunity in the MPN market, where existing therapies provide symptomatic relief but fail to alter the underlying disease course.
View full company profile